Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: Final results of a phase II trial

Annals of Oncology

Volumn 16, Issue 10, 2005, Pages 1624-1631

  Schmid, Peter ^a   Krocker, J ^b   Jehn, C ^a   Michniewicz, K ^b   Lehenbauer Dehm, S ^a   Eggemann, H ^b   Heilmann, V ^c   Kummel S ^a   Schulz, C O ^a   Dieing, A ^a   Wischnewsky, M B ^d   Hauptmann, S ^e   Elling, D ^b   Possinger, K ^a   Flath, B ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b MARTIN LUTHER KRANKENHAUS   (Germany)

^c UNIVERSITY HOSPITAL ULM   (Germany)

^d UNIVERSITY OF BREMEN   (Germany)

^e MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Adjuvant treatment; Docetaxel; Gemcitabine; Liposomal doxorubicin; Locally advanced breast cancer; Neoadjuvant treatment; Primary chemotherapy

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; ANTIBIOTIC AGENT; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; KI 67 ANTIGEN; LIVER ENZYME; METHOTREXATE; NON PEGYLATED LIPOSOMAL DOXORUBICIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ALOPECIA; ANEMIA; ANTIGEN EXPRESSION; ARTICLE; ASTHENIA; AXILLARY LYMPH NODE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SIZE; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; EARLY CANCER; FEBRILE NEUTROPENIA; FEVER; HUMAN; HUMAN TISSUE; INFECTION COMPLICATION; LIVER DYSFUNCTION; LIVER TOXICITY; LYMPH NODE METASTASIS; MUCOSA INFLAMMATION; NAIL DISEASE; NAUSEA; NEUTROPENIA; PATIENT MONITORING; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SKIN DEFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 27144439325     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi321     Document Type: Article

References (55)

1. Mauriac L, MacGrogan G, Avril A et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: A unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 1999; 10: 47-52.
2. Broet P, Scholl SM, de la Rochefordiere A et al. Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: An updated analysis of a randomized trial. Breast Cancer Res Treat 1999; 58: 151-156.
3. Semiglazov VF, Topuzov EE, Bavli JL et al. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol 1994; 5: 591-595.
4. Jakesz R. Comparison of pre- vs. postoperative chemotherapy in breast cancer patients: Four-year results of Austrian Breast & Colorectal Cancer Study Group (ABCSD) Trial 7. Proc Am Soc Clin Oncol 2000; 19: Abstr 125.
5. Makris A, Powles TJ, Ashley SE et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 1998; 9: 1179-1184.
6. Van der Hage JA, Van de Velde CJH, Julien JP et al. Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol 2001; 19: 4224-4237.
7. Wolmark N, Wang J, Mamounas E et al. Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001; 30: 96-102.
8. Kuerer HM, Newman LA, Smith TL et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460-469.
9. Fisher B, Bryant J, Wolmark N et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-2685.
10. Kaufmann M, von Minckwitz G, Smith R et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: Review and recommendations. J Clin Oncol 2003; 21: 2600-2608.
11. Estevez LG, Cuevas JM, Anton, A et al. Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: Efficacy and correlation with biological markets in a phase II, multicenter center. Clin Cancer Res 2003; 9: 686-692.
12. Gradishar WJ. Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer. Phase II study: Preliminary results. Oncology 1997; 11 (Suppl 8): 15-18.
13. Buzdar AU, Hortobagyi GN, Theriault RL et al. Prospective randomized trial of taxol (Tax) alone versus Fluorouracil, Doxorubicin, Cyclophosphamide (FAC) as an induction therapy in patients with operable breast cancer (Br Ca). Proc Am Soc Clin Oncol 1999; 18: Abstr 273.
14. Smith IC, Heys SD, Hutcheon AW et al. Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with doxetaxel. J Clin Oncol 2002; 20: 1456-1466.
15. Pouillart P, Fumoleau P, Romieu G et al. Final results of a phase II randomized, parallel study of doxorubicin/cyclophosphamide (AC) and doxorubicin/taxol (paclitaxel) (AT) as neoadjuvant treatment of local-regional breast cancer. Proc Am Soc Clin Oncol 1999; 18: Abstr 275.
16. Vinholes J, Bouzid K, Salas F. Preliminary results of a multicentre phase III trial of taxotere and doxorubicin (AT) versus 5-fluouracil, doxorubicin and cyclophosphamide (FAC) in patients (Pts) with unresectable locally advanced breast cancer (ULAB). Proc Am Soc Clin Oncol 2001; 20: Abstr 101.
17. Luporsi E, Vanlemmens L, Coudert B. 6 cyles of FEC 100 vs 6 cycles of epirubicin-docetaxel (ED) as neoadjuvant chemotherapy in operable breast cancer patients (Pts): Preliminary results of a randomized phase II trial of GIREC S01. Proc Am Soc Clin Oncol 2000; 19: Abstr 355.
18. Evans T, Yellowlees A, Foster E et al. Phase III randomised trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: An anglo-celtic cooperative oncology group study. J Clim Oncol 2005; 23: 2988-2995.
19. Conte PF, Gennari A, Donati S et al. Gemcitabine plus epirubicin plus taxol in advanced breast cancer: A phase II study. Breast Cancer Res Treat 2001; 68: 171-179.
20. Sanchez-Rovira P, Jaen A, Gonzalez E, et al. Biweekly gemcitabine, doxorubicin and paclitaxel as first-line treatment in metastatic breast cancer: Final results from a phase II trial. Oncology 2001; 15 (2 Suppl 3): 44-47.
21. Conte PF, Gennari A, Santoro A, for the GET Preoperative Group. Induction chemotherapy in operable breast cancer: A multicenter Italian phase II study with the GET regimen. Proc Am Soc Clin Oncol 2003; 22: Abstr 140.
22. Harris L, Batist G, Belt R, Rovira D et al. for the TLC D-99 study group. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002; 94: 25-36.
23. Batist G, Ramakrishnan G, Sekhar Rao C et al. Reduced cardiotoxicity and preserved antitumour efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001; 19: 1444-1454.
24. Chan D, Davidson N, Juozaityte E et.al. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann Oncol 2004; 15: 1527-1534.
25. Zoli W, Ricotti L, Barzanti F et al. Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines. Int J Cancer 1999; 80: 413-416.
26. Heinemann V, Schukz L, Issels RD, Plunkett W. Gemcitabine: A modulator of intracellular nucleotide and deoxynucleotide metabolism. Semin Oncol 1995; 22 (Suppl 11): 11-18.
27. Plunkett W, Huang P, Xu YZ et al. Gemcitabine: Metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995; 22 (Suppl 11): 3-10.
28. Huang P, Plunkett W. Induction of apoptosis by gemcitabine. Semin Oncol 1995; 22 (Suppl 11): 19-25.
29. Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W. Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 1991; 27: 258-262.
30. Abbruzzese JL, Grunewald R, Weeks EA et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9: 491-498.
31. Veerman G, Ruiz van Haperen VW, Vermorken JB et al. Antitumor activity of prolonged as compared with bolus administration of 2′,2′-difluorodeoxycytidine in vivo against murine colon tumors. Cancer Chemother Pharmacol 1996; 38: 335-342.
32. Maurel J, Zorrilla M, Puertolas T et al. Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors. Anticancer Drugs 2001; 12: 713-717.
33. Schmid P, Sohweigert M, Beinert T et al. Prolonged infusion of gemcitabine in advanced solid tumors: A phase-I-study. Anticancer Drugs 2005; 23: 139-146.
34. 2) levels. Invest New Drugs 1997; 15: 115-121.
35. Akrivakis K, Schmid P, Flath B et al. Prolonged infusion of gemcitabine in stage IV breast cancer: A phase-I-study. Anticancer Drugs 1999; 10: 525-531.
36. Schmid P, Akrivakis K, Flath B et al. A phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anticancer Drugs 1999; 10: 625-631
37. Schmid P, Krocker J, Dieing A et al. Primary chemotherapy with gemcitabine, myocet and docetaxel: Results of a phase I trial. Anticancer Drugs 2005; 16: 21-29.
38. Sinn HP, Schmid H, Junkermann H et al. Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy. Geburtshilfe Frauenheilkd 1994; 54: 552-558.
39. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologie 1987; 3: 138-140.
40. Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: An overview of 61 randomized trials among 28,896 women. N Engl J Med 1998; 319: 1681-1692.
41. Early Breast Cancer Trialists' Collaborative Groupl Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 1998; 352: 930-942.
42. Von Minckwitz G, Costa SD, Raab G et al. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: A randomized, controlled, open phase IIb study. J Clin Oncol 2001; 19: 3506-3515.
43. Von Minckwitz G, Blohmer JU, Raab G et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: The GEPARTRIO pilot study. Ann Oncol 2005; 16: 56-63.
44. Buzdar AU, Singletary SE, Theriault RL et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 1999; 17: 3412-3417.
45. Penault-Llorca F, Sastre X, Fiche M. Pathological response to neoadjuvant chemotherapy (CT): Final results of a prospective randomized trial of 4AT vs 4AC as induction therapy in patients with operable breast cancer using Sataloff classification. Breast Canc Res Treat 1999; 57: 67 (Abstr 248).
46. Bear HD, Anderson S, Brown A et al. National Surgical Adjuvant Breast and Bowel Project Protocol B-27. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27, J Clin Oncol 2003; 21: 4165-4174.
47. Untch M, Konecny G, Ditsch N. Dose-dense sequential epirubicin/ paclitaxel as preoperative treatment of breast cancer: Results of a randomized AGO study. Proc Am Soc Clin Oncol 2002; 21: Abstr 133.
48. Schneeweiss A, Huober J, Sinn HP et al. Gemcitabine, epirubicin and docetaxel as primary 'systemic therapy in patients with early breast cancer: Results of a multicenter phase I/II study. Eur J Cancer 2005: 40: 243-238.
49. Hamm J, Wilson J, Lembersky BC et al. Neoadjuvant chemotherapy with gemcitabine, epirubicin and paclitaxel in locally advanced breast cancer: A phase II trial of the NSABP Foundation Research Group. Breast Cancer Res Treat 2003; 82 (Suppl 1): Abstr 235.
50. Yardley DA, Whitworth P, Greco FA. Neoadjuvant gemcitabine, epirubicin and paclitaxel: Preliminary results from a multicenter phase II trial in inflammatory and locally advanced breast cancer. Breast Cancer Res Treat 2003; 82 (Suppl 1): Abstr 237.
51. Jackisch C, von Minckwitz G, Costa S. Adapting in-vivo chemosensitivity for further evaluation of preoperative chemotherapy in patients with operable primary breast cancer. Interim analysis of the gepartriotrial Breast Cancer Res Treat 2003; 82: Abstr 228.
52. Untch M, Kahlert S, Moebus V et al. Negative steroid receptors are a good predictor for response to preoperative chemotherapy in breast cancer (BC) - results of a randomised trial. Proc Am Soc Clin Oncol 2003; 22: 9 (Abstr 35).
53. Buzdar AU, Valero V, Theriault RL et al. Pathological complete response to chemotherapy is related to hormone receptor status. Breast Cancer Res Treat 2003; 82: Abstr 302.
54. Eiermann W, Paepke S, Appfelstaedt J et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 2001; 12: 1527-1532.
55. Semiglazov VF, Semiglazov V, Ivanov V et al. The relative efficacy of neoadjuvant endocrine therapy vs chemotherapy in postmenopausal women with ER-positive breast cancer. J Clin Oncol 2004; 22 (14S): 519.